AbbVie Inc. (BVMF:ABBV34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 2.31T +23.5% |
| Revenue (ttm) | 327.71B +9.5% |
| Net Income | 18.75B -13.3% |
| EPS | 10.59 -13.2% |
| Shares Out | n/a |
| PE Ratio | 123.28 |
| Forward PE | 16.90 |
| Dividend | 1.41 (1.72%) |
| Ex-Dividend Date | Apr 14, 2026 |
| Volume | 264 |
| Open | 79.36 |
| Previous Close | 78.83 |
| Day's Range | 79.36 - 80.70 |
| 52-Week Range | 58.81 - 82.33 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
AbbVie reports ‘positive’ results from Phase 3 EPCORE DLBCL-4 trial
AbbVie (ABBV) announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell engaging bispecific antibody, and lenalidomide, compared to rituximab ...
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Topline results from Phase 3 EPCORE ® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-...
AbbVie announces CHMP opinion recommending approval of upadacitinib for AA
AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending the approval of upadacitinib for the treatment...
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key secondary ...
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs for those living with the chronic, unpredictabl...
AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease
AbbVie (ABBV) announced the U.S. FDA has approved Skyrizi for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy…
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syri...
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2026 financial results on Friday, July 31, 2026, before the market opens.
AbbVie's $11 Billion Immunology Bet
In this week's edition of InnovationRx, we look at AbbVie's new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more. To get ...
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026
250 Women Entrepreneurs Have Been Selected to Join a Multi-Week Skill-Building, Mentorship, and Networking Program BOTOX® Cosmetic Will Award 20 Participants With $20,000 Grants Each to Help Take Thei...
AbbVie’s Allergan Aesthetics receives approval for Boey in Canada
Allergan Aesthetics, an AbbVie (ABBV) company, announced Health Canada has approved Boey for the temporary improvement in the appearance of moderate to severe lines between the eyebrows in adult patie...
Apogee Therapeutics price target raised to $135 from $97 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Apogee Therapeutics (APGE) to $135 from $97 and keeps a Sector Perform rating on the shares after AbbVie (ABBV)…
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
Canada is the first country to approve a new botulinum neurotoxin serotype for aesthetic use Boey ® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved for th...
Apogee Therapeutics moved to No Rating at BofA
BofA moved to No Rating on Apogee Therapeutics (APGE) after the company agreed to be acquired by AbbVie (ABBV) for $135.11 per share in cash. AbbVie sees strategic alignment with…
AbbVie price target raised to $273 from $265 at Canaccord
Canaccord raised the firm’s price target on AbbVie (ABBV) to $273 from $265 and keeps a Buy rating on the shares. The firm updated its model following its anounced acquisition…
AbbVie announces European Commission approval for Skyrizi
AbbVie (ABBV) announced that the European Commission has approved Skyrizi for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis who…
AbbVie announces European Commission approval of Maviret
AbbVie (ABBV) announced that the European Commission approved Maviret, an oral pangenotypic direct-acting antiviral therapy for the treatment of acute hepatitis C virus infection in adults and childre...
AbbVie announces EU approval of Skyrizi for pediatric patients
AbbVie (ABBV) announced that the European Commission has approved SKYRIZI for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis who…
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
MAVIRET ® (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV) infection with compensated liver disease (with or without cirrhosis) in ad...
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
SKYRIZI ® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis 1 Approval was based on the pivotal Phase 3 OptIMMize-1...
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
Clear Street reiterated a Buy rating and $53 price target on Evommune (EVMN), saying Abbvie’s (ABBV) proposed acquisition of Apogee (APGE) provides a positive readthrough to Evommune’s pipeline. In pa...
Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE
Micron (MU) is entering a new strategic partnership with Anthropic as Needham raises its price target on the AI memory stock. Credo Technology (CRDO) gets a new bull in Evercore ISI after it initiated...
AbbVie to Buy Apogee Therapeutics for $10.9 Billion
Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, ...
AbbVie Transcript: M&A announcement
The acquisition brings a portfolio of differentiated, long-acting antibody assets to strengthen the immunology and respiratory pipelines, with the lead asset targeting atopic dermatitis and potential mega blockbuster sales. The $10.9B all-cash deal is expected to be accretive by 2032, leveraging clinical and commercial synergies for long-term growth.